Send to

Choose Destination
See comment in PubMed Commons below
Front Microbiol. 2015 Apr 9;6:282. doi: 10.3389/fmicb.2015.00282. eCollection 2015.

Drug repurposing as an alternative for the treatment of recalcitrant bacterial infections.

Author information

Department of Microbiology and Parasitology, Faculty of Medicine, Universidad Nacional Autónoma de México Mexico City, Mexico.
Terrametrix, CA USA.
Epigenetics of Cancer Laboratory, Division of Basic Research, National Institute of Genomic Medicine Mexico City, Mexico.
Centro Médico Coyoacán, Mexico City Mexico.


Bacterial infection remains one of the leading causes of death worldwide, and the options for treating such infections are decreasing, due the rise of antibiotic-resistant bacteria. The pharmaceutical industry has produced few new types of antibiotics in more than a decade. Researchers are taking several approaches toward developing new classes of antibiotics, including (1) focusing on new targets and processes, such as bacterial cell-cell communication that upregulates virulence; (2) designing inhibitors of bacterial resistance, such as blockers of multidrug efflux pumps; and (3) using alternative antimicrobials such as bacteriophages. In addition, the strategy of finding new uses for existing drugs is beginning to produce results: antibacterial properties have been discovered for existing anticancer, antifungal, anthelmintic, and anti-inflammatory drugs. In this review, we discuss the antimicrobial properties of gallium compounds, 5-fluorouracil, ciclopirox, diflunisal, and some other FDA-approved drugs and argue that their repurposing for the treatment of bacterial infections, including those that are multidrug resistant, is a feasible strategy.


5-fluorouracil; bacterial infections; ciclopirox; diflunisal; drug repurposing; gallium

PubMed Commons home

PubMed Commons

How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Frontiers Media SA Icon for PubMed Central
    Loading ...
    Support Center